Benefits
GAD + adjustment disorders vs diazepam (PIVOTAL Phase III)
Syunyakov 2016 (PMID 27636931, Ter Arkhiv 88:73-86) — multicenter randomized comparative Phase III study of afobazole vs diazepam. 5 investigating centers, 150 patients aged 18-60 (60 GAD + 90 adjustment disorders). Afobazole 30 mg/day (n=100) vs diazepam 30 mg/day (n=50) for 30 days. Placebo-susceptible patients excluded after 7-day placebo run-in. PRIMARY ENDPOINT: HAMA total score change. RESULTS: Afobazole NON-INFERIOR to diazepam; SUPERIOR on several variables including SAFETY PROFILE. Reduction of anxiety in afobazole group EXCEEDED diazepam (HAMA difference 2.93 [0.67-5.19], p=0.01). Disease severity reduction: 72% afobazole vs lower diazepam. Foundational pivotal RCT supporting Russian regulatory approval and OTC status.
Cardiovascular anxiety (Grigorian 2008)
Grigorian 2008 (PMID 18379478, Zh Nevrol Psikhiatr Im S S Korsakova) — 32 patients with cardiovascular diseases and neurotic stress-related psychopathologies (ICD-10 F40-F45). Afobazole 30-60 mg/day (mean 50 mg) for 6 weeks alongside basic somatotropic therapy. 70% RESPONDER RATE on Hamilton anxiety scale (HAM-A) and CGI. Improvement began week 1 and increased to day 42. Phobic, somatized, anxiety-depressive symptoms gradually reduced. Well-tolerated. Important real-world cardiovascular comorbidity evidence.
Activating profile WITHOUT sedation
Distinguishing pharmacology from benzodiazepines: ANXIOLYTIC ACTION WITH ACTIVATING COMPONENT — opposite of typical sedating benzodiazepines. Beneficial for patients needing daytime function preservation. Established in Neznamov 2001 (PMID 11548440) clinical trial in 30 patients with anxiety/anxious-asthenic disorders showing afobazole anxiolytic without sedative or myorelaxant effects. Pharmaco-EEG investigation confirmed.
Sigma-1 receptor mechanism (UNIQUE)
Distinguishing mechanism: SIGMA-1 RECEPTOR (Sigma1R) AGONIST/CHAPERONE — affects calcium signaling, receptor trafficking, ER stress responses. Mechanism distinct from all benzodiazepines (GABA-A modulators). Combined with GABA-A enhancement and indirect Sigma2R effects. Foundation for unique pharmacology and safety profile.
Neuroprotective effects
Sigma-1 receptor activation provides neuroprotective effects in ischemic stroke models — increases glial cell survival, prevents glial cell activation and nitrosative stress (Katnik 2016). BDNF and NGF release promotion. Mechanism for additional benefits beyond pure anxiolysis. Theoretical relevance to neurodegeneration prevention.
Reversible MAO-A inhibition
Afobazole reversibly inhibits MAO-A — secondary mechanism contributing to mood effects. Less prominent than sigma-1 effects but contributes to overall pharmacology. Theoretical relevance to depression adjunct use.
Mechanism of action
Sigma-1 receptor (Sigma1R) chaperone agonism
PRIMARY MECHANISM: Sigma-1 receptor agonism — protein in endoplasmic reticulum that regulates calcium signaling and receptor trafficking. Sigma1R chaperone activity enhances GABA-A receptor function and prevents stress-induced reductions in benzodiazepine site binding. Moderate affinity (Ki = 5.9 μM for Sigma1R). Mechanism distinct from benzodiazepines.
GABA-A receptor enhancement (indirect, via Sigma1R chaperone)
Through Sigma1R chaperone activity, afobazole enhances GABA-A receptor function and prevents stress-induced GABA-A dysfunction. INDIRECT mechanism distinct from direct benzodiazepine binding. Mechanism for anxiolysis without typical benzodiazepine sedation/dependence profile.
BDNF and NGF release promotion
Promotes BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) release. Mechanism for neuroprotective effects and possible antidepressant adjunct properties. Distinct from acute receptor modulation.
MT1 melatonin receptor agonism, MT3 antagonism
Affects melatonin receptor system — MT1 agonism, MT3 antagonism. Mechanism may contribute to mood and circadian effects. Less clinically validated than sigma-1 effects.
Reversible MAO-A inhibition
Reversibly inhibits MAO-A enzyme — secondary mechanism for mood-modulating effects. Reversible inhibition vs irreversible MAO inhibitors (less interaction risk).
Multi-target neuropsychopharmacology
Beyond above mechanisms: serotonergic effects, possible cytoprotective effects via Sigma-1. Multi-target profile explaining broad therapeutic effects with relatively benign safety profile.
Clinical trials
Multicenter randomized comparative Phase III study (Syunyakov TS, Neznamov GG 2016, Ter Arkhiv 88(8):73-86, doi:10.17116/terarkh201688873-86, PMID 27636931). V.V. Zakusov Research Institute of Pharmacology, Moscow.
150 patients aged 18-60 years across 5 investigating centers. 60 patients with generalized anxiety disorder (GAD) + 90 patients with adjustment disorders (AD). Simple structure of anxiety disorders without concurrent mental, neurological, or somatic disorders. Randomized to afobazole 30 mg/day (n=100) or diazepam 30 mg/day (n=50) for 30 days. Placebo-susceptible patients excluded after 7-day placebo run-in. Withdrawal syndrome evaluated 10 days post-treatment.
Afobazole NON-INFERIOR to diazepam in primary HAMA endpoint. SUPERIOR on several variables INCLUDING SAFETY PROFILE. Reduction of anxiety in afobazole group EXCEEDED diazepam (HAMA difference 2.93 [0.67-5.19], p=0.01). 72% disease severity reduction in afobazole group. Foundational pivotal Phase III evidence supporting Russian regulatory approval and OTC status.
Standard clinical trial with pharmaco-EEG investigation (Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB 2001, Eksp Klin Farmakol 64(2):15-19, PMID 11548440).
30 patients with anxiety and anxious-asthenic disorders and premorbid individual asthenic profile traits. Pharmaco-EEG monitoring.
Afobazole exhibited ANXIOLYTIC ACTION WITH ACTIVATING COMPONENT in absence of sedative and myorelaxant effects. Distinguishing pharmacology from benzodiazepines confirmed. Pharmacogenetic concept of anxioselectivity validated as methodological approach. Foundational positive clinical trial supporting development.
Real-world cardiology study (Grigorian RS et al. 2008, Zh Nevrol Psikhiatr Im S S Korsakova, PMID 18379478).
32 patients aged 18-60 with cardiovascular diseases and neurotic stress-related psychopathologies and somatoform disorders (ICD-10 F40-F45). Afobazole 30-60 mg/day (mean 50 mg) for 6 weeks alongside basic somatotropic therapy. 29 completed.
70% RESPONDERS (n=21) on HAM-A and CGI. Improvement began week 1 and increased to day 42. PHOBIC, SOMATIZED, ANXIETY-DEPRESSIVE symptoms gradually reduced to complete reduction. Well-tolerated. Important real-world evidence for cardiovascular comorbidity context — common clinical scenario.
About this ingredient
Afobazole (international nonproprietary name FABOMOTIZOLE; chemical: 5-ethoxy-2-[2-(morpholino)-ethylthio]-benzimidazole hydrochloride; brand names AFOBAZOLE, AFABAZOL) is a SELECTIVE NON-BENZODIAZEPINE ANXIOLYTIC developed at the V.V. ZAKUSOV RESEARCH INSTITUTE OF PHARMACOLOGY in Moscow, Russia. Synthesized late 1990s; clinical registration granted 2006 following Phase III multicenter trial (n=150).
Manufactured by Pharmstandard (Russia); available OVER-THE-COUNTER. Belongs to 2-MERCAPTOBENZIMIDAZOLE derivative class. UNIQUE PHARMACOLOGY: SIGMA-1 RECEPTOR CHAPERONE AGONIST as primary mechanism — affects calcium signaling, receptor trafficking, ER stress responses.
Sigma1R chaperone activity ENHANCES GABA-A receptor function and PREVENTS STRESS-INDUCED reductions in benzodiazepine site binding. Mechanism distinct from all benzodiazepines (direct GABA-A modulators). Additional mechanisms: GABA-A enhancement (indirect, via Sigma1R chaperone), BDNF and NGF release promotion, MT1 receptor agonism / MT3 antagonism (melatonin receptor system), reversible MAO-A inhibition, neuroprotective effects via Sigma-1 (Katnik 2016 — increases glial cell survival, prevents nitrosative stress in ischemic stroke).
DESIGN PHILOSOPHY: pharmacogenetic concept of ANXIOSELECTIVITY — designed for anxiolytic activity without benzodiazepine drawbacks (sedation, muscle relaxation, cognitive impairment, dependence, withdrawal). Phase III trial confirmed: NON-INFERIOR to diazepam efficacy with SUPERIOR safety profile. RUSSIAN REGULATORY APPROVAL: GENERALIZED ANXIETY DISORDER (GAD), neurasthenia, adjustment disorders, sleep disorders, alleviation of withdrawal syndromes, cardiovascular comorbid anxiety.
OVER-THE-COUNTER status. CIS countries with similar approvals. NOT FDA-approved in US — gray-zone supplement/research compound with limited US availability.
CLINICAL EVIDENCE BASE: SYUNYAKOV 2016 PMID 27636931 PIVOTAL Phase III multicenter RCT (n=150) vs diazepam — non-inferior efficacy with superior safety; NEZNAMOV 2001 PMID 11548440 foundational pilot trial demonstrating activating anxiolytic without sedation; GRIGORIAN 2008 PMID 18379478 real-world cardiovascular comorbid anxiety study (70% responders); Voronin 2016 sigma-1 mechanism studies; Katnik 2016 ischemic stroke neuroprotection. Russian-language predominance with some English translations of Phase III evidence. EVIDENCE: 2/5 reflects: (1) Syunyakov 2016 PIVOTAL Phase III RCT vs diazepam — most rigorous Russian peptide/anxiolytic trial in available literature, (2) Neznamov 2001 foundational clinical pharmacology evidence, (3) Grigorian 2008 real-world cardiovascular anxiety evidence, (4) Russian OTC regulatory approval reflecting accumulated evidence, (5) unique Sigma-1 chaperone mechanism with rigorous preclinical characterization, (6) limited rigorous Western RCT evidence, (7) gray US regulatory status.
SAFETY: Excellent — major advantages over benzodiazepines including no dependence/withdrawal/sedation/motor/cognitive impairment. Best positioned as: (a) GAD ALTERNATIVE for those wanting to avoid benzodiazepine dependence/cognitive effects under Russian medical supervision, (b) ADJUSTMENT DISORDERS adjunct, (c) CARDIOVASCULAR-COMORBID ANXIETY adjunct (where benzodiazepines may complicate cardiac care), (d) DAYTIME ANXIETY treatment preserving cognitive/motor function (activating profile vs sedating benzodiazepines), (e) NOT FDA-approved — research compound status in US warrants regulatory caution, (f) gradual onset (5-7 days for full effect) — not for acute panic, (g) Russian-only published Phase III evidence limits Western clinical adoption. Honest framing: afobazole has perhaps the most pharmacologically and methodologically sophisticated profile among Russian peptide/non-peptide anxiolytics — pivotal Phase III RCT vs diazepam showed non-inferiority with superior safety profile, Sigma-1 chaperone mechanism is biochemically rigorous, OTC Russian regulatory approval since 2006 reflects accumulated clinical evidence.
The activating anxiolytic profile (vs sedating benzodiazepines) is clinically distinctive. Western RCT replication and FDA approval pathway not pursued due to Russian-developed compound status. Reasonable for anxiety treatment in countries where approved under medical supervision; gray status in US warrants caution but pharmacology and evidence are substantial.